No Data
No Data
Inovio Pharmaceuticals' Earnings Call: Progress Amid Challenges
Inovio Pharmaceuticals Inc. Stock Slips 6.7%, Underperforms Competitors
H.C. Wainwright Initiates Inovio Pharmaceuticals(INO.US) With Hold Rating, Announces Target Price $3
RBC Capital Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Cuts Target Price to $5
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Aims for INO-3107 Regulatory Submission by Mid-2025 While Addressing Key Manufacturing Issues